Neurosense Therapeutics News - June 29, 2026
🔴 NRSN is trading 5.5% down today after meeting Phase 2b ALS study endpoint
NRSN is trading 5.5% down now at $0.72 after announcing it achieved the primary endpoint in its Phase 2b ALS study, a key milestone for its lead asset...
NeuroSense's Sub-Dollar Stock Gets a Jolt From Alzheimer's Data and Insider Cash — But Can an Eight-Patient Study Justify Real Conviction?
Shares shifted as NeuroSense Therapeutics (NRSN) ticked up 3% to $0.78 ahead of its June 30 Q1 earnings report, capping a string of catalysts: fresh...
🟢 NRSN is trading 3% up today ahead of Q1 earnings and positive clinical updates
NRSN is trading 3% up at $0.78 as investors position ahead of its June 30, 2026, Q1 earnings report and react to positive clinical and financing updates. •...
NeuroSense Therapeutics Ltd Q1 2026 Earnings Preview: What Analysts Expect on June 30, 2026
Analysts expect NeuroSense Therapeutics to report a quarterly loss of $0.14 per share on zero revenue, with the current stock price of $1.42 trailing...